Salix Pharmaceuticals Announces 4Q and FY2013 Financial Results Conference Call and Webcast

Salix's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

RALEIGH, NC, February 13, 2014 -

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report fourth quarter and full year 2013 financial results following the close of the U.S. financial markets on Thursday, February 27, 2014.

The Company will host a conference call at 4:30 p.m. ET on Thursday, February 27, 2014. Interested parties can access the conference call by way of web cast or telephone. The live web cast will be available at www.salix.com. A replay of the web cast will be available at the same location. The telephone numbers to access the live conference call are (888) 339-3507 (U.S. and Canada) or (719) 325-2276 (international.) The access code for the live call is 198635. The telephone numbers to access the replay of the call are (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international). The access code for the replay is 6025289.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and commercialize them through the Company’s 500-member specialty sales force.

Salix trades on the NASDAQ Global Select Market under the ticker symbol “SLXP”.

For more information, please visit our Website at www.salix.com

or contact the Company at 919-862-1000. Follow us on Twitter (@SalixPharma) and Facebook (). Information on our Twitter feed, Facebook page and web site is not incorporated in our SEC filings.

News Source : Salix Pharmaceuticals Announces 4Q and FY2013 Financial Results Conference Call and Webcast

Copy this html code to your website/blog to embed this press release.